Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3200882 · 2 trials · 2 indications
PK: Cmax of LY3200882
PK: AUC of LY3200882
| Arm | Type | Description |
|---|---|---|
| LY3200882 | EXPERIMENTAL | LY3200882 administered orally. |
| Itraconazole + LY3200882 | EXPERIMENTAL | Itraconazole + LY3200882 administered orally. |
| LY3200882 Schedule 1 Escalation | EXPERIMENTAL | - |
| LY3200882 Schedule 2 Escalation | EXPERIMENTAL | - |
| LY3200882 Schedule 1 Expansion | EXPERIMENTAL | - |
| LY3200882 Schedule 2 Expansion | EXPERIMENTAL | - |
| LY3200882 + LY3300054 | EXPERIMENTAL | - |
| LY3200882 + Gemcitabine + nab-Paclitaxel | EXPERIMENTAL | - |
| LY3200882 + Cisplatin + Radiation | EXPERIMENTAL | - |
| Japanese Arm LY3200882 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| LY3200882 | DRUG | Administered orally. |
| Itraconazole | DRUG | Administered orally. |
| LY3300054 | DRUG | Administered intravenously |
| Gemcitabine | DRUG | Administered intravenously |
| nab-Paclitaxel | DRUG | Administered intravenously |
| Cisplatin | DRUG | Administered intravenously |
| Intensity Modulated Radiotherapy | RADIATION | - |
Inclusion Criteria: * Healthy males or postmenopausal females, as determined by medical history and physical examination Exclusion Criteria: * Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable o...
LY3200882 is an investigational small molecule being studied for the treatment of solid tumors. It is currently in Phase 1 clinical development, with trials enrolling participants who have solid tumors. The drug is also being studied in healthy participants for drug interaction purposes.
LY3200882 is being developed by Eli Lilly and Company, a pharmaceutical company listed on the New York Stock Exchange under the ticker symbol LLY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with solid tumors.
LY3200882 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied in early-stage trials to assess its safety, tolerability, and pharmacokinetics in participants with solid tumors and in healthy volunteers.
LY3200882 is being studied in two Phase 1 clinical trials. The first trial, NCT02937272, is an active study in participants with solid tumors, with an enrollment of 223 participants across multiple countries. The second trial, NCT03792139, is a completed drug interaction study in healthy participants with 23 participants.
LY3200882 is the sole name provided for this investigational drug. No alternative names have been reported. It is a small molecule being developed by Eli Lilly and Company for the potential treatment of solid tumors, and it is currently in Phase 1 clinical trials.